Brief: Cyteir Therapeutics Inc Reports Q3 Loss Per Share Of $0.31
07/11/2022 21:38
Nov 7 (Reuters) - Cyteir Therapeutics Inc CYT.O :
* CYTEIR THERAPEUTICS REPORTS THIRD QUARTER 2022 FINANCIAL
RESULTS
AND OPERATIONAL HIGHLIGHTS
* Q3 LOSS PER SHARE $0.31
* INITIAL DATA FROM CYT-0851 MONOTHERAPY SOLID TUMOR PHASE 2
COHORTS ARE NOW EXPECTED IN Q1 OF 2023
* INITIAL DATA FROM PHASE 1 COMBINATION SOLID TUMOR COHORTS
ARE
EXPECTED IN FIRST HALF OF 2023
Source text for Eikon: ID:nBw3Bds0Za
Further company coverage: CYT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cyteir Therapeutics
See all newsBrief: Cyteir Announces Timeline For Voluntarily Delisting From Nasdaq
Brief: Cyteir Therapeutics Timothy Romberger Resigned From Board & All Of Its Committees
Brief: Ongoing Results From A Dose Expansion Cohort Of Cyt-0851 In Combination With Capecitabine In Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity And Generally Well Tolerated Safety Profile
Brief: Cyteir Therapeutics Announces Discontinuation Of Cyt-0851 Development Program And Planned Liquidation And Dissolution
Brief: Cyteir Says Preliminary Ongoing Results With CYT-0851 In Combination With Capecitabine Or Gemcitabine In Advanced Solid Tumors Show Early Clinical Activity And Generally Well Tolerated Safety Profile